Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- WORLD NEWS IN BRIEF
April 15, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
April 15, 2002
- The 122nd Anniversary Meeting of the Pharmaceutical Society of Japan
April 15, 2002
- Bills for Amended PAL Submitted to the Diet
April 15, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
April 15, 2002
- Korosho Details 5-year Plan for Policy Evaluation
April 15, 2002
- DIAGNOSTIC NEWS IN BRIEF
April 15, 2002
- Cost Calculation Method Needs Improvements: Budget Committee
April 15, 2002
- Korosho Prepares Decision Tree for Medical Devices
April 15, 2002
- Outline of Relief System for Victims of Tissue Engineering Products Recommended
April 15, 2002
- Terumo Latin America Established in Miami
April 15, 2002
- Plan of Reducing Subsidies to Public Corporations Approved
April 15, 2002
- Nabelin Fuji Science Ties Up with 2 Medical Devices Wholesalers
April 15, 2002
- REGULATORY NEWS IN BRIEF
April 15, 2002
- Oticon: New Hearing Aid Adapto
April 15, 2002
- BULLETIN
April 15, 2002
- Medical Institutions Can Advertise from April 1
April 15, 2002
- Let the Change Be Your Friend: Mr Ogawa of Nippon Roche
April 15, 2002
- Sanofi-Synthelabo Looks for New Type of Partnership in Japan
April 15, 2002
- LDP Opposed to Experimental Deregulation in Healthcare Field
April 15, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…